NASDAQ: PDSBPds Biotechnology Corp Stock
$3.25+0.05 (+1.56%)
Updated Apr 24, 2024
PDSB Price
$3.25
Fair Value Price
$1.06
Market Cap
$119.21M
52 Week Low
$2.59
52 Week High
$10.27
P/E
-2.34x
P/B
4.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.27
Operating Cash Flow
-$34M
Beta
1.23
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PDSB Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PDSB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PDSB ($3.25) is overvalued by 207.54% relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PDSB ($3.25) is not significantly undervalued (207.54%) relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PDSB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PDSB due diligence checks available for Premium users.
Be the first to know about important PDSB news, forecast changes, insider trades & much more!
PDSB News
Valuation
PDSB fair value
Fair Value of PDSB stock based on Discounted Cash Flow (DCF)
Price
$3.25
Fair Value
$1.06
Overvalued by
207.54%
PDSB ($3.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PDSB ($3.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PDSB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PDSB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.34x
Industry
15.69x
Market
41.27x
PDSB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.56x
Industry
5.86x
PDSB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PDSB's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.9M
Profit Margin
0%
PDSB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$59.4M
Liabilities
$33.3M
Debt to equity
1.27
PDSB's short-term assets ($59.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PDSB's short-term assets ($59.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PDSB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PDSB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.5M
Investing
$0.0
Financing
$10.8M
PDSB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PDSB vs Biotech Stocks
Pds Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.